Command Palette

Search for a command to run...

Clinical Trials · NCT01558271

A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus

CompletedPhase 3Liraglutide (Approved)
Phase
Phase 3
Recruitment status
Completed
Sponsor
Eli Lilly and Company
Enrollment
492
Start date
Mar 2012
Locations
14 sites, Japan
Primary endpoint
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks
View Liraglutide compound reference